Lenacapavir is available in both oral tablet form and as subcutaneous injections. It is available as oral tablets and ...

Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

Trump administration funding cuts and dismantling of USAID force a shift from HIV elimination back to treatment.

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus (EBV)-driven lymphomas. The findings, ...

Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...

The drug, in June, received FDA approval as the first twice-yearly pre-exposure prophylaxis (PrEP) option to reduce the risk ...

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

HealthLink talked with a Seattle-based physician about why the newly approved drug could be a game-changer in preventing HIV.

The US Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV.

The US Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that offers long-lasting protection ...